This service contract is to support continued preclinical development studies post-grant support, or support de novo preclinical studies through the Catalyze Preclinical (CatPC) program open solicitation and award process. The primary purpose of the CatPC is to provide services to facilitate and accelerate the development of novel technologies for the prevention, diagnosis, and/or treatment of heart, lung, blood, and sleep (HLBS) disorders from late optimization through regulatory approval filing. Projects may enter via successful completion and approval for advancement of a technology from other Catalyze grant initiatives, or may apply directly to CatPC to support technology development activities that fall within the program scope. For successful applications, CatPC will fill the gap between end-stage optimization conducted during the product definition stage, and regulatory approval filing in anticipation of clinical study initiation. Thus, CatPC will be a critical and required portion of the Catalyze Program to provide a continuous translational pipeline from discovery to first-in-human trials.